Clinical Trial Update: BKM120 in Cancers With PIK3CA Activating Mutations [Phase 2]

View source ↗

Summary

A Phase 2 trial of buparlisib (BKM120) in cancers with activating PIK3CA mutations has been withdrawn. The conditions listed include lung cancer, breast cancer,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cholangiocarcinoma
• Colorectal Cancer
• Lung Cancer

Drugs mentioned

• BKM120 (Buparlisib) (buparlisib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Lung Cancer, Breast Cancer | Phase 2 | Status: WITHDRAWN